67,082 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Nicholas Investment Partners LP

Nicholas Investment Partners LP purchased a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 67,082 shares of the company’s stock, valued at approximately $2,088,000. Nicholas Investment Partners LP owned about 0.07% of Viridian Therapeutics at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of VRDN. Morgan Stanley boosted its position in Viridian Therapeutics by 805.6% in the 4th quarter. Morgan Stanley now owns 1,738,225 shares of the company’s stock valued at $54,094,000 after buying an additional 1,546,284 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Viridian Therapeutics by 29.6% in the 4th quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company’s stock worth $174,650,000 after purchasing an additional 1,280,161 shares during the last quarter. Commodore Capital LP boosted its position in shares of Viridian Therapeutics by 35.4% in the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company’s stock worth $68,152,000 after purchasing an additional 1,275,000 shares during the last quarter. Jennison Associates LLC bought a new position in shares of Viridian Therapeutics in the 4th quarter worth $35,915,000. Finally, State Street Corp boosted its position in shares of Viridian Therapeutics by 35.7% in the 4th quarter. State Street Corp now owns 3,466,560 shares of the company’s stock worth $107,879,000 after purchasing an additional 912,394 shares during the last quarter.

Insider Activity

In other news, Director Fairmount Funds Management Llc purchased 1,176,470 shares of the company’s stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $17.00 per share, with a total value of $19,999,990.00. Following the purchase, the director directly owned 5,090,928 shares of the company’s stock, valued at $86,545,776. This trade represents a 30.05% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 2.40% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have recently issued reports on VRDN shares. Wells Fargo & Company reduced their price target on Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating on the stock in a research report on Tuesday, March 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Viridian Therapeutics in a research report on Monday, April 20th. Truist Financial reduced their price target on Viridian Therapeutics from $36.00 to $33.00 and set a “buy” rating on the stock in a research report on Tuesday, April 21st. The Goldman Sachs Group reduced their price target on Viridian Therapeutics from $36.00 to $31.00 and set a “buy” rating on the stock in a research report on Tuesday, April 7th. Finally, Evercore set a $26.00 price target on Viridian Therapeutics in a research report on Friday, May 15th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Viridian Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $36.14.

Viridian Therapeutics Stock Performance

Shares of Viridian Therapeutics stock opened at $16.35 on Friday. The company has a market capitalization of $1.69 billion, a PE ratio of -4.92 and a beta of 0.90. Viridian Therapeutics, Inc. has a 12 month low of $13.18 and a 12 month high of $34.29. The company has a current ratio of 15.15, a quick ratio of 15.15 and a debt-to-equity ratio of 0.10. The stock’s fifty day simple moving average is $15.96 and its 200 day simple moving average is $25.29.

Viridian Therapeutics (NASDAQ:VRDN) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.16. The business had revenue of $0.14 million for the quarter, compared to the consensus estimate of $0.04 million. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The firm’s revenue was up 95.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.87) EPS. On average, research analysts predict that Viridian Therapeutics, Inc. will post -3.87 EPS for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.